the Quillay tree, which is a rare evergreen endemic to Chile. According to the media, the long-term availability of these trees is in doubt. Malaria is considerably more lethal in Africa than COVID-19. According to WHO data, it claimed 386,000 lives in Africa in 2019, compared to 212,000 verified COVID-19 fatalities over the last 18 months.
According to the WHO, Africa, which has a population of 1.3 billion people, accounts for 94% of malaria infections and fatalities. Parasites transferred to individuals by infected mosquito bites cause this preventable illness. Fever, vomiting, and exhaustion are some of the common symptoms. Although the vaccine is only around 30% effective at preventing severe malaria in children, it is the only one licensed. It was authorized by the European Union’s pharmaceutical agency in 2015, citing the benefits above dangers.
Ashley Birkett oversees Path’s worldwide malaria vaccine program. Path is a non-profit global health organization that has financially supported the vaccine research alongside GSK and the three-country pilot. He said, “This is how we fight malaria, layering imperfect tools on top of each other”.
According to the report released by the researchers in April, another malaria vaccine, named R21/Matrix-M, produced by scientists at the University of Oxford in the United Kingdom demonstrated nearly 77 percent effectiveness in a one year research where 450 children in Burkina Faso participated. It is still undergoing trials. GSK expressed its support for the WHO guideline.
Thomas Breuer, senior global health officer of GSK, released a statement saying, “This long-awaited landmark decision can reinvigorate the fight against malaria in the region at a time when progress on malaria control has stalled”. GSK shares remained unchanged in New York following the news, which arrived after the conclusion of trading in the company’s London-listed shares.
